An IL-7 fusion protein that shows increased thymopoietic ability

Sian M. Henson, Robert Snelgrove, Tracy Hussell, Dominic J. Wells, Richard Aspinall

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

The role of IL-7 during thymopoiesis has led to it being the focus of a number of therapeutic interventions. However, its small size and pleiotropic nature present problems for thymus-directed therapies. We have created a fusion molecule between the extracellular N-terminal domain of CCR9 and IL-7, which has the potential to overcome these difficulties. This novel fusion protein retains the thymopoietic activity of IL-7 and the ligand-binding ability of CCR9. As a thymopoietic agent, compared with IL-7, it shows an enhanced retention in the thymus, increased de novo T cell production, and increased thymic output Old mice receiving the fusion protein show improved CD8 T cell responses and reduced viral load after infection with influenza virus compared with those receiving IL-7. This chimeric molecule offers a novel therapeutic strategy that may result in the production of an effective immunorestorative agent.

Original languageEnglish
Pages (from-to)4112-4118
Number of pages7
JournalJournal of Immunology
Volume175
Issue number6
DOIs
Publication statusPublished - 15 Sep 2005
Externally publishedYes

Fingerprint

Interleukin-7
Proteins
Thymus Gland
T-Lymphocytes
Orthomyxoviridae
Viral Load
Therapeutics
Ligands
Infection

ASJC Scopus subject areas

  • Immunology

Cite this

An IL-7 fusion protein that shows increased thymopoietic ability. / Henson, Sian M.; Snelgrove, Robert; Hussell, Tracy; Wells, Dominic J.; Aspinall, Richard.

In: Journal of Immunology, Vol. 175, No. 6, 15.09.2005, p. 4112-4118.

Research output: Contribution to journalArticle

Henson, Sian M. ; Snelgrove, Robert ; Hussell, Tracy ; Wells, Dominic J. ; Aspinall, Richard. / An IL-7 fusion protein that shows increased thymopoietic ability. In: Journal of Immunology. 2005 ; Vol. 175, No. 6. pp. 4112-4118.
@article{7e28059276d84a0891a207ade302a5a7,
title = "An IL-7 fusion protein that shows increased thymopoietic ability",
abstract = "The role of IL-7 during thymopoiesis has led to it being the focus of a number of therapeutic interventions. However, its small size and pleiotropic nature present problems for thymus-directed therapies. We have created a fusion molecule between the extracellular N-terminal domain of CCR9 and IL-7, which has the potential to overcome these difficulties. This novel fusion protein retains the thymopoietic activity of IL-7 and the ligand-binding ability of CCR9. As a thymopoietic agent, compared with IL-7, it shows an enhanced retention in the thymus, increased de novo T cell production, and increased thymic output Old mice receiving the fusion protein show improved CD8 T cell responses and reduced viral load after infection with influenza virus compared with those receiving IL-7. This chimeric molecule offers a novel therapeutic strategy that may result in the production of an effective immunorestorative agent.",
author = "Henson, {Sian M.} and Robert Snelgrove and Tracy Hussell and Wells, {Dominic J.} and Richard Aspinall",
year = "2005",
month = "9",
day = "15",
doi = "10.4049/jimmunol.175.6.4112",
language = "English",
volume = "175",
pages = "4112--4118",
journal = "Journal of Immunology",
issn = "0022-1767",
publisher = "American Association of Immunologists",
number = "6",

}

TY - JOUR

T1 - An IL-7 fusion protein that shows increased thymopoietic ability

AU - Henson, Sian M.

AU - Snelgrove, Robert

AU - Hussell, Tracy

AU - Wells, Dominic J.

AU - Aspinall, Richard

PY - 2005/9/15

Y1 - 2005/9/15

N2 - The role of IL-7 during thymopoiesis has led to it being the focus of a number of therapeutic interventions. However, its small size and pleiotropic nature present problems for thymus-directed therapies. We have created a fusion molecule between the extracellular N-terminal domain of CCR9 and IL-7, which has the potential to overcome these difficulties. This novel fusion protein retains the thymopoietic activity of IL-7 and the ligand-binding ability of CCR9. As a thymopoietic agent, compared with IL-7, it shows an enhanced retention in the thymus, increased de novo T cell production, and increased thymic output Old mice receiving the fusion protein show improved CD8 T cell responses and reduced viral load after infection with influenza virus compared with those receiving IL-7. This chimeric molecule offers a novel therapeutic strategy that may result in the production of an effective immunorestorative agent.

AB - The role of IL-7 during thymopoiesis has led to it being the focus of a number of therapeutic interventions. However, its small size and pleiotropic nature present problems for thymus-directed therapies. We have created a fusion molecule between the extracellular N-terminal domain of CCR9 and IL-7, which has the potential to overcome these difficulties. This novel fusion protein retains the thymopoietic activity of IL-7 and the ligand-binding ability of CCR9. As a thymopoietic agent, compared with IL-7, it shows an enhanced retention in the thymus, increased de novo T cell production, and increased thymic output Old mice receiving the fusion protein show improved CD8 T cell responses and reduced viral load after infection with influenza virus compared with those receiving IL-7. This chimeric molecule offers a novel therapeutic strategy that may result in the production of an effective immunorestorative agent.

UR - http://www.scopus.com/inward/record.url?scp=24744434924&partnerID=8YFLogxK

U2 - 10.4049/jimmunol.175.6.4112

DO - 10.4049/jimmunol.175.6.4112

M3 - Article

VL - 175

SP - 4112

EP - 4118

JO - Journal of Immunology

JF - Journal of Immunology

SN - 0022-1767

IS - 6

ER -